Compugen to Release Second Quarter Results on Thursday, August 4, 2022
Compugen Ltd. (Nasdaq: CGEN) will announce its second quarter financial results on August 4, 2022, before U.S. markets open. A conference call and webcast will take place at 8:30 AM ET for management to discuss the results and provide corporate updates. Compugen is a clinical-stage cancer immunotherapy company focused on computational target discovery, featuring proprietary drug candidates like COM701 and COM902, both in Phase 1 trials. Their partnership with Bayer and AstraZeneca also highlights their innovative drug development.
- Compugen's proprietary candidates COM701 and COM902 are in Phase 1 trials, indicating ongoing development of innovative therapies.
- Partnerships with Bayer and AstraZeneca enhance potential for successful drug development and commercialization.
- None.
HOLON, Israel, July 21, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Company will release its second quarter financial results on Thursday, August 4, 2022, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.
To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link.
Following the live webcast, a replay will be available on the Company's website.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody, for the treatment of solid tumors, in Phase 1 as a single agent and in dual, and triple combinations; COM902, a potential best-in-class monoclonal antibody targeting TIGIT for the treatment of solid and hematological tumors, undergoing Phase 1 studies as a single agent and in dual combination with COM701. Partnered programs include bapotulimab, an antibody targeting ILDR2, in Phase 1 development, licensed to Bayer under a research and discovery collaboration and license agreement, and a TIGIT/PD-1 bispecific derived from COM902 (AZD2936) in Phase 1/2 development by AstraZeneca through a license agreement for the development of bispecific and multi-specific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Investor Relations contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications Compugen Ltd.
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-release-second-quarter-results-on-thursday-august-4-2022-301590731.html
SOURCE Compugen Ltd.
FAQ
When will Compugen release its second quarter results?
What time is the conference call for Compugen's Q2 results?
What are Compugen's current drug candidates?
